Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HER2/CEP17 ratio predicts residual cancer burden after neoadjuvant dual HER2 blockade: real-world data in patients with primary HER2-amplified breast cancer.

Virchows Archiv : an international journal of pathology·2025
Same author

Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer.

British journal of cancer·2025
Same author

Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial.

Nature cancer·2025
Same author

Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.

Clinical cancer research : an official journal of the American Association for Cancer Research·2021
Same author

The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8.

Clinical cancer research : an official journal of the American Association for Cancer Research·2021
Same author

Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs.

Molecular cancer research : MCR·2021

Related Experiment Video

Updated: Feb 5, 2026

A Bedside, Single Burr Hole Approach to Multimodality Monitoring in Severe Brain Injury
06:18

A Bedside, Single Burr Hole Approach to Multimodality Monitoring in Severe Brain Injury

Published on: March 26, 2019

9.6K

SABCS 2017 pathology: from bench to bedside.

Zsuzsanna Bago-Horvath1

  • 1Clinical Institute of Pathology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.

Memo
|September 18, 2018
PubMed
Summary
This summary is machine-generated.

The 40th International San Antonio Breast Cancer Symposium highlighted novel breast cancer therapies. Key findings include the limited benefit of prolonged zoledronic acid and the EndoPredict assay

Keywords:
BisphosphonatesEndoPredictMolecular pathologySABCS pathology

More Related Videos

Manufacture of a Multi-Purpose Low-Cost Animal Bench-Model for Teaching Tracheostomy
10:06

Manufacture of a Multi-Purpose Low-Cost Animal Bench-Model for Teaching Tracheostomy

Published on: May 18, 2019

6.0K
DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens
10:38

DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens

Published on: February 1, 2020

7.9K

Related Experiment Videos

Last Updated: Feb 5, 2026

A Bedside, Single Burr Hole Approach to Multimodality Monitoring in Severe Brain Injury
06:18

A Bedside, Single Burr Hole Approach to Multimodality Monitoring in Severe Brain Injury

Published on: March 26, 2019

9.6K
Manufacture of a Multi-Purpose Low-Cost Animal Bench-Model for Teaching Tracheostomy
10:06

Manufacture of a Multi-Purpose Low-Cost Animal Bench-Model for Teaching Tracheostomy

Published on: May 18, 2019

6.0K
DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens
10:38

DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens

Published on: February 1, 2020

7.9K

Area of Science:

  • Oncology
  • Translational Research
  • Genetics

Background:

  • The 40th International San Antonio Breast Cancer Symposium convened to discuss innovative therapeutic approaches for breast cancer.
  • A key focus was the synergy between basic research and drug development for novel therapy concepts.
  • Advances in understanding tumor heterogeneity and BRCA2 mutations were presented.

Purpose of the Study:

  • To present and discuss innovative preclinical and clinical findings in breast cancer research.
  • To explore novel therapeutic strategies and collaborations in drug development.
  • To assess the clinical utility of prognostic and predictive assays in breast cancer treatment.

Main Methods:

  • Presentation of preclinical data on selective estrogen receptor covalent antagonists (SERCAs) and immune-modulating effects of demethylating agents.
  • Characterization of BRCA2 mutations and molecular analysis of intratumoral heterogeneity and lobular breast cancer evolution.
  • Clinical trial results on adjuvant bisphosphonate treatment duration (SUCCESS A study) and predictive value of the EndoPredict assay (ABCSG 34 trial).

Main Results:

  • Prolonged adjuvant zoledronic acid administration for 5 years did not improve patient survival in the SUCCESS A study.
  • The EndoPredict multigenomic assay identified patients unlikely to benefit from neoadjuvant endocrine or chemotherapy in the ABCSG 34 trial.
  • Preclinical data suggested potential of SERCAs and immune-modulating effects of demethylating agents.

Conclusions:

  • Extended adjuvant bisphosphonate therapy may not offer survival benefits for all breast cancer patients.
  • The EndoPredict assay shows promise in personalizing neoadjuvant treatment decisions.
  • Continued research into novel therapeutic targets and predictive biomarkers is crucial for advancing individualized breast cancer care.